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Introduction: Circulating tumor cells (CTCs) have been studied in breast cancer with the CellSearch® system. Given
the low CTC counts in non-metastatic breast cancer, it is important to evaluate the inter-reader agreement.
Methods: CellSearch® images (N = 272) of either CTCs or white blood cells or artifacts from 109 non-metastatic (M0) and
22 metastatic (M1) breast cancer patients from reported studies were sent to 22 readers from 15 academic laboratories and
8 readers from two Veridex laboratories. Each image was scored as No CTC vs CTC HER2- vs CTC HER2+. The 8 Veridex
readers were summarized to a Veridex Consensus (VC) to compare each academic reader using % agreement and kappa
(κ) statistics. Agreement was compared according to disease stage and CTC counts using the Wilcoxon signed rank test.
Results: For CTC definition (No CTC vs CTC), the median agreement between academic readers and VC was 92% (range 69
to 97%) with a median κ of 0.83 (range 0.37 to 0.93). Lower agreement was observed in images from M0 (median 91%,
range 70 to 96%) compared to M1 (median 98%, range 64 to 100%) patients (P< 0.001) and from M0 and <3CTCs (median
87%, range 66 to 95%) compared to M0 and ≥3CTCs samples (median 95%, range 77 to 99%), (P < 0.001). For CTC HER2
expression (HER2- vs HER2+), the median agreement was 87% (range 51 to 95%) with a median κ of 0.74 (range 0.25 to 0.90).
Conclusions: The inter-reader agreement for CTC definition was high. Reduced agreement was observed in M0 patients
with low CTC counts. Continuous training and independent image review are required.Introduction
Circulating tumor cells (CTCs) can be identified in the per-
ipheral blood of patients with solid tumors even in early
disease stages and their detection and characterization have
the potential to lead towards personalized treatment strat-
egies in breast and other cancers [1-3].
Several technologies exist for CTC detection, but Cell-
Search® (Veridex, Raritan, NJ, USA) is the only one that* Correspondence: michail.ignatiadis@bordet.be
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reproduction in any medium, provided the orhas received Food and Drug Administration (FDA)
clearance to be used as an aid in monitoring patients with
metastatic breast, colorectal and prostate cancer. Com-
pared to other CTC assays [4], CellSearch® is so far the
only semi-automated system and has contributed consid-
erably to the development of standards for CTC enumer-
ation. In breast cancer, a multicenter study has shown
that ≥5 CTCs/7.5 ml of blood were detected in 49% of
177 patients before starting a new treatment for meta-
static disease and their detection was independently
associated with worse progression-free and overall sur-
vival (PFS and OS) [5]. Subsequently, other studies
have confirmed these results [6-8]. The value of CTC
detection by CellSearch® in non-metastatic breast cancerral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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7.5 ml was reported in 23% of 115 patients with large op-
erable and locally advanced breast cancer before neoadju-
vant chemotherapy and was independently associated with
worse outcome [9]. In another study, detection of ≥1 CTC/
7.5 ml by CellSearch® at the time of surgery and before the
administration of adjuvant chemotherapy in 24% of 302 pa-
tients was associated with decreased PFS and OS [10]. In
the SUCCESS study, ≥1 CTC/23 ml were detected by Cell-
Search® in 21.5% of 2,026 patients with early breast cancer
before adjuvant chemotherapy and the detection was inde-
pendently associated with poor outcome [11]. In another
study ≥1 CTC/30 ml of blood were detected in 19% of 404
patients with stage-I to -III breast cancer before surgery and
their detection was independently associated with shorter
distant disease-free survival [12]. Beyond enumeration, CTC
characterization holds the promise to serve as a liquid bi-
opsy to tailor treatment decisions [1,2]. As an example, as
HER2 protein overexpression or gene amplification in the
primary tumor is currently required for administering anti-
HER2 treatment in breast cancer [13], HER2 status on
CTCs has also been investigated in breast cancer using
CellSearch® and other technologies [14-18].
More than 400 studies have included CTCs as a bio-
marker [19]. These include interventional studies asses-
sing the value of CTCs as a treatment decision tool in the
metastatic and non-metastatic setting [20,21]. Two studies
have validated the analytical performance of CellSearch®
for CTC detection in metastatic breast cancer [22,23]. In
the metastatic setting, the main contributor to inter-
laboratory variation was variability among the readers in
image interpretation [23,24]. In non-metastatic breast can-
cer (BC) more than half of women with detectable CTCs
have only 1 CTC/blood volume processed [9-12]. There-
fore, in this setting, image interpretation is crucial, espe-
cially if CTC detection is to be used as a tool to decide on
secondary adjuvant treatment strategies in the context of
a clinical trial. Moreover, no study has addressed potential
problems in image interpretation when HER2 expression
on CTCs is investigated using CellSearch®, which is an im-
portant prerequisite for interventional studies using CTCs
in trials testing HER2-directed therapies.
Therefore, we performed an international study to evalu-
ate the inter-reader agreement in the classification of
CellSearch® images as CTC and interpretation of HER2-
staining on these images. Moreover, we came up with
consensus guidelines for image interpretation in the non-
metastatic breast cancer setting that were subsequently
endorsed by CTC experts participating in this study.
Methods
Patient and samples
CellSearch® images from blood samples used for the de-
tection of CTCs and characterization of CTC HER2protein expression by CellSearch® from breast cancer pa-
tients were retrieved for this study. The blood samples
were processed at one of the three different laboratories;
the Institut Jules Bordet, Belgium (IJB), the Institut Curie,
France (IC), and the University of Hamburg, Germany
(UH), respectively. The IJB dataset included CellSearch®
images from women with non-metastatic (M0) and meta-
static (M1) breast cancer treated according to the standard
of care in Belgium [17]. The IC dataset consisted of Cell-
Search® images from women with inflammatory M0 breast
cancer participating in the BEVERLY-I and -II phase-2 tri-
als [25,26]. The UH dataset included CellSearch® images
from women receiving neoadjuvant chemotherapy in the
GeparQuattro and GeparQuinto studies (M0 cohort)
[16,27] and women from the Detect Study (M1 cohort)
[18]. From each patient sample, a subset of CellSearch®
images (images of either CTCs or white blood cells or
artifacts) and not the full set of CellSearch® images were
provided by investigators from the three independent, aca-
demic labs to the principal investigator at IJB who was re-
sponsible for the central coordination of the study. Due to
technology limitations, at the time the study was initiated,
it was not possible to send the full set of CellSearch® im-
ages from each patient sample. All CellSearch® images
used in the present study are from previously reported
studies of CTC detection in breast cancer [16-18,25-27].
All women participating in these studies provided in-
formed consent and each study was approved by the re-
spective institutions' ethical committees. The present
study was approved by the IJB ethical committee (CE
2035). Informed consent for the present study was waived
by the IJB ethical committee.
Readers
The IJB lab sent the blinded CellSearch® images by
email to twenty-two readers from one US and fourteen
European academic laboratories as well as to eight readers
from two Veridex laboratories. Each CellSearch® image was
evaluated independently of the other images. All readers
had already received the appropriate training provided by
Veridex for the CellSearch® system, which includes training
in image interpretation.
Definition of CTC and HER2-positive CTC
In CellSearch®, a CTC is defined as an epithelial cell adhe-
sion molecule (EpCAM)-positive cell (round to oval and
sometimes polygonal or elongated in shape and at least
4 μm in size) that has positive immunofluoresence stain-
ing for a Cytokeratin (CK) (clone C11 and A53-B/A2) epi-
thelial marker and positive staining for the nuclear dye
4',6-diamidino-2-phenylindole (DAPI) (the nuclear area
should be smaller than the cytoplasmic area and at least
50% of the nucleus should be co-located with the cyto-
plasm). The CTC must also be negative for the leukocyte





n = 131 (100%) n = 272 (100%)
Dataset
Institute Jules Bordet 34 (26) 60 (22)
Institute Curie 60 (46) 114 (42)
University of Hamburg 37 (28) 98 (36)
Age, years
≤50 58 (44) 108 (40)
>50 66 (51) 147 (54)
Unknown 7 (5) 17 (6)
ER
Negative 54 (41) 106 (39)
Positive 68 (52) 139 (51)
Unknown 9 (7) 27 (10)
HER2
Negative 103 (79) 193 (71)
Positive 15 (11) 44 (16)
Unknown 13 (10) 35 (13)
Histology grade
1 5 (4) 6 (2)
2 46 (35) 85 (31)
3 69 (53) 147 (54)
Unknown 11 (8) 34 (13)
Histology
Ductal 99 (76) 202 (74)
Lobular 10 (8) 12 (4)
Other 7 (5) 18 (7)
Unknown 15 (11) 40 (15)
Stage
M0 109 (83) 215 (79)
M1 22 (17) 57 (21)
CTC count1
<5 CTCs 90 (69) 150 (55)
≥5 CTCs 40 (30) 120 (44)
Unknown 2 (1) 2 (1)
Systemic therapy before
blood sample collection2
No 87 (65) 168 (62)
Yes 31 (24) 62 (23)
Unknown 15 (11) 42 (15)
1One patient with two samples (<5 CTCs and ≥ 5CTCs) was included; 2two
patients with samples before and after treatment were included. ER, estrogen
receptor; CTC, circulating tumor cell; M0, non-metastatic; M1, metastatic.
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score CTCs with HER2 immunofluoresence staining in-
tensity of 2+, 3+ as HER2-positive and were provided with
reference CellSearch® images from breast cancer cell lines
(MCF7, BT20, T47D, MDA-MB-453, SKBR3, BT474) with
different levels of HER2 expression according to Riethdorf
et al. [16]. The readers scored each image as follows: No
CTC, CTC/HER2-negative (CTC HER2-), or CTC/HER2-
positive (CTC HER2+).
Statistics
Results from the eight Veridex readers were summarized
to a Veridex consensus (VC) in order to compare each aca-
demic reader using percentage (%) agreement and kappa
(κ) statistics. We followed the Koch and Landis classifica-
tion to interpret obtained κ values: concordance was con-
sidered bad if κ was less than 0.20, poor if κ was 0.20 to
0.40, moderate if κ was 0.40 to 0.60, good if κ was 0.60 to
0.80, and almost perfect if κ was above 0.81 [28]. VC was
reached when there was >60% agreement between Veridex
readers as to whether or not an image was a CTC. When
there was <60% agreement by the Veridex readers for an
image, this image was not included in any of the subse-
quent comparisons. If the VC was that the image was a
CTC, then there had to be >60% agreement on the CTC
being either HER2- or HER2+. If there was <60% agree-
ment about the HER2 positivity or negativity among the
Veridex readers for a CTC, this image was not included in
any of the subsequent comparisons.
For each of the 22 academic readers, percentage (%)
agreement with VC was calculated for the CTC detection
question (no CTC versus CTC) and for the question of
HER2 expression on CTCs (CTC HER2- versus CTC
HER2+). In order to understand problems related to Cell-
Search® image interpretation, we compared the locations
in the distributions of the agreement (%) between VC and
the academic readers according to the dataset (IJB versus
IC versus UH), disease stage (M0 versus M1), number of
detected CTCs in the entire sample (≥5 CTCs versus <5
CTCs) and administration of systemic treatment before
blood sampling (yes versus no) using non-parametric tests
(Wilcoxon signed rank and Freedman test). Moreover,
within M0 patient samples, we interrogated whether there
was different agreement according to the number of CTCs
detected in the entire sample (≥3 CTCs versus <3 CTCs)
using the Wilcoxon signed rank test. Finally, we studied
CellSearch® images with <70% agreement between VC and
academic readers in order to understand reasons for dis-
cordance between readers.
Results
CellSearch® images and patient characteristics
A total of 272 CellSearch® images from 131 patients were
analyzed. Table 1 provides information on relevant studydemographics. The majority of CellSearch® images ana-
lyzed were from patients with M0 breast cancer, with <5
CTCs in their blood sample and from patients for whom
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the administration of systemic treatment (Table 1).
Veridex consensus (VC)
For each image, the results from the eight Veridex readers
were summarized to a VC, as explained in the Methods
section. For CTC detection, VC was reached for 267 (98%)
of 272 images with an average percent agreement for CTC
versus no CTC between the eight Veridex readers of 97%
(median 100%, range 63% to 100%). Of the 267 images,
157 (59%) were considered CTCs. For interpretation of
HER2 staining on the CTC, VC was obtained for 155
(99%) out of 157 CTCs with an average percent agreement
for HER2- versus HER2+ between the eight Veridex
readers of 98% (median 100%, range 63% to 100%): 71
(46%) of 155 CTCs were considered as HER2 + .
Agreement between academic readers and Veridex
consensus for CTC definition
For the question of whether an image was a CTC (no
CTC versus CTC), the median agreement between the
academic readers and VC was 92% (range 69% to 97%),Table 2 Agreement (%) between academic readers and Verid
No CTC versus CTC
RDs N Agreement (%) Kappa statistic Kappa agreement
A 267 91.8% 0.83 Almost perfect
B 267 91.4% 0.82 Almost perfect
C 267 92.5% 0.84 Almost perfect
D 267 91.8% 0.83 Almost perfect
E 266 95.1% 0.90 Almost perfect
F 267 92.1% 0.84 Almost perfect
G 267 91.4% 0.82 Almost perfect
H 267 91.4% 0.82 Almost perfect
I 267 92.1% 0.84 Almost perfect
J 267 83.9% 0.65 Substantial
K 220 87.3% 0.74 Substantial
L 266 92.9% 0.85 Almost perfect
M 220 87.3% 0.74 Substantial
N 267 95.9% 0.92 Almost perfect
O 267 96.6% 0.93 Almost perfect
P 267 94.4% 0.88 Almost perfect
Q 218 91.7% 0.83 Almost perfect
R 218 91.7% 0.83 Almost perfect
S 220 92.7% 0.85 Almost perfect
T 266 69.2% 0.37 Fair
U 267 91.4% 0.82 Almost perfect
V 220 91.8% 0.84 Almost perfect
CTC, circulating tumor cell; RDs, readers; N, number of images. Kappa Agreement, b
0.61 to 0.80 Substantial; 0.81 to 1.00 Almost Perfect.with a median κ statistic of 0.83 (range 0.37 to 0.93)
(Table 2). We then asked whether agreement between
the academic readers and VC was different according to
the dataset (IJB versus IC versus UH), disease stage (M0
versus M1), CTC counts (<5 versus ≥5) and administra-
tion of systemic treatment before blood sampling (yes
versus no). We observed significantly lower agreement
between academic readers and VC for CellSearch® im-
ages from patients of the IJB dataset compared to the
other datasets, from patients with M0 compared to M1
disease, <5 CTCs compared to ≥5 CTCs, and blood sam-
ples drawn after the administration of systemic treat-
ment as compared to samples drawn before systemic
treatment (Table 3, Additional file 1: Table S1 and
Additional file 2: Table S2, online). CellSearch® images
from samples with <5 CTCs were present more fre-
quently in M0 (146 of 213 images, 68%) compared to
M1 patients (4 of 57 images, 7%) (Pearson chi-square
test, P <0.001) and in the IJB dataset, (52 of 60 images,
87%) compared to the UH (22 of 96 images, 22%) and
the IC dataset (76 of 114 images, 67%) (P <0.001).
When only images from M0 patients samples wereex consensus (VC)
CTC HER2- versus CTC HER2+
N Agreement (%) Kappa statistic Kappa agreement
155 81.3% 0.63 Substantial
155 81.3% 0.63 Substantial
155 90.3% 0.81 Almost perfect
155 71.6% 0.47 Moderate
154 93.5% 0.87 Almost perfect
155 87.1% 0.75 Substantial
155 91.0% 0.82 Almost perfect
155 88.4% 0.78 Substantial
155 91.6% 0.84 Almost perfect
155 76.8% 0.55 Moderate
117 79.5% 0.59 Moderate
154 94.8% 0.90 Almost perfect
117 90.6% 0.82 Almost perfect
155 92.3% 0.85 Almost perfect
155 92.9% 0.86 Almost perfect
155 85.2% 0.72 Substantial
113 84.1% 0.69 Substantial
113 85.8% 0.73 Substantial
117 86.3% 0.73 Substantial
154 51.3% 0.25 Fair
155 91.0% 0.82 Almost perfect
117 82.1% 0.66 Substantial
elow 0.00 Poor; 0.00 to 0.20 Slight; 0.21 to 0.40 Fair; 0.41 to 0.60 Moderate;
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samples with <3 CTCs (median 87%, range 66% to 95%)
compared to those from samples where ≥ 3CTCs were de-
tected (median 95%, range 77% to 99%), (P <0.001).
Agreement between academic readers and Veridex
consensus (VC) for HER2 expression on CTCs
When only the images that were CTCs according to VC
were analyzed for HER2 protein expression (CTC HER2-
versus CTC HER2+), the median agreement between the
academic readers and VC was 87% (range 51% to 95%),
with a median κ statistic of 0.74 (range 0.25 to 0.90)
(Table 2).
Analysis of CellSearch® images with <70% agreement
between academic readers and Veridex consensus (VC)
There were many images with excellent agreement be-
tween academic readers and VC, such as images of intact
CTCs (Figure 1A). In order to understand the reasons for
discordance in image interpretation, we focused on images
with <70% agreement between the academic readers and
VC. We identified 25 images with <70% agreement for the
CTC question (CTC versus no CTC) and 14 images
with <70% agreement for the HER2 expression ques-
tion (HER2- versus HER2+ CTCs). Disagreement was
observed for images of CTCs with CK staining that
surrounded the nucleus but was either incomplete or
granular (Figure 1B). A total of 16 of the 25 imagesTable 3 Percent agreement between academic readers
and Veridex consensus (VC) overall and according to
dataset, disease stage, circulating tumor cell (CTC) count




All 92 69 to 97
Dataset
Institute Jules Bordet 81 61 to 97 <0.001
Institute Curie 97 73 to 99
University of Hamburg 94 69 to 98
Stage
M0 91 70 to 96 <0.001
M1 98 64 to 100
CTC count
<5 CTCs 88 66 to 95 <0.001
≥5 CTCs 97 74 to 100
Systemic therapy before
blood sample collection
No 92 74 to 96 <0.001
Yes 89 55 to 97
CTC, circulating tumor cell; M0, Non-metastatic, M1, metastatic.with <70% agreement for the CTC question were con-
sidered by some academic readers as CTCs, whereas
the VC was that these images were not CTCs. These
included images displaying the same morphology in all
channels (Figure 1C,D) or a nucleus larger than the cyto-
plasm or <50% inside the cytoplasm and with cytokeratin
(CK) staining not surrounding the nucleus (Figure 1E,F).
Images with <70% agreement between academic readers
and VC for the HER2 expression question were images
from CTCs with intermediate HER2 staining (neither too
strong nor absent).
Discussion
To our knowledge, this is the first study to evaluate the
inter-reader agreement for CTC detection in both M1
and M0 breast cancer in a large international multicen-
ter study comprising 15 centers from Europe and the
United States. Our results show that the inter-reader
agreement is high for CTC definition and for character-
izing HER2 expression on CTCs.
Lower inter-reader agreement for CTC definition was
observed for CellSearch® images of samples from pa-
tients with M0 disease, with low CTC counts, samples
from the IJB dataset, and samples drawn after the ad-
ministration of systemic treatment. CellSearch® images
of samples with low CTC counts were more frequently
observed in the IJB compared to the other datasets and
in M0 compared to M1 disease and this can partly ex-
plain the lower inter-reader agreement in these groups.
In a recently reported study of CTC detection by Cell-
Search® at the time of surgery in patients with early
breast cancer, increasing CTC counts were associated
with increasing hazard ratio (HR) for disease progres-
sion. The presence of ≥1 CTC, ≥2 CTCs and ≥3 CTCs
was associated with a HR of 4.6, 5.5 and 6.7, respectively
[10]. Although, this increase in HRs can be attributed to
the increase in the number of CTCs, the data from the
present analysis imply that this might be also due to the
lower false CTC-positive cases in women with increasing
CTC counts. Finally, a possible explanation for the lower
inter-reader agreement in samples drawn after the ad-
ministration of systemic treatment is the presence in
these samples of granular CTCs that have been demon-
strated to be mainly apoptotic, and to be a source of
inter-reader disagreement in a previous study [23].
There are some limitations in the way the present valid-
ation study was conducted. Although CellSearch® image
selection was performed by three independent, academic
laboratories, a selection bias towards either CellSearch®
images that are easy (typical CTC images) or difficult to
interpret (not typical CTC images) cannot be excluded.
Moreover, the readers were provided with a subset of Cell-
Search® images (images of either CTCs or white blood
cells or artifacts) and not the full set of CellSearch® images
Figure 1 Example of an intact circulating tumor cell (CTC) (A), a granular CTC (B) and of images with no CTCs (C,D,E,F) as they display
the same morphology in all channels (C,D) or have a nucleus larger than the cytoplasm or not 50% inside the cytoplasm and
cytokeratin staining not surrounding the nucleus (E,F). DAPI, 4',6-diamidino-2-phenylindole.
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lection cannot be excluded. Moreover, the readers were
scoring images but were not able to use the Cell Select
tool of the CellSearch® system, which allows relocation of
a cellular image in the cartridge and study of its character-
istics in more detail. As the technology evolves, one can
imagine that the exchange of CellSearch® images for cen-
tral image review will be more easily performed.
The above limitations may partly explain some of the
discrepancies observed between readers. Although overall
inter-reader agreement was high, agreement was lower in
images from M0 patients with <3 CTCs. In order to im-
prove the performance of academic readers, especially in
the setting of non-metastatic breast cancer with low CTC
counts, we propose the following: 1) images displaying
identical morphology in all channels (CK, DAPI and
HER2 if performed) or images with a nucleus larger than
the cytoplasm or <50% inside the cytoplasm should not be
considered as CTCs; 2) the authors reporting studies onCTCs using CellSearch® should clearly indicate whether
their CTC definition includes only intact CTCs (complete
CK staining surrounding the nucleus) or whether it also
includes granular CTCs (CK staining that surrounds the
nucleus but is either granular or incomplete); 3) in cases
of blood samples from M0 patients with low CTC counts
(<3 CTCs) evaluation of images by at least two independ-
ent readers - ideally from different labs - should be per-
formed. Such an independent image review is applied
in the ongoing European Organization for Research
and Treatment of Cancer (EORTC) Treat CTC trial
(ClinicalTrials.gov Identifier: NCT01548677). This trial
is testing the value of CTC detection to decide for second-
ary adjuvant treatment in BC.
We propose that investigators conducting studies on
CTCs in non-metastatic breast cancer follow these guide-
lines for CellSearch® image interpretation. The present
study might also be a model for similar experiments re-
garding other image-based CTC technologies. This could
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CTC detection and characterization, and accelerate the
clinical development of CTC-related biomarkers.Conclusions
This is the first study to evaluate the inter-reader agree-
ment for CTC detection in both metastatic and non-
metastatic BC in a large international multicenter study
comprising 15 centers from Europe and the United States.
We demonstrated that inter-reader agreement using
CellSearch® was high overall but was reduced in non-
metastatic breast cancer patients with low CTC counts.
This study resulted in consensus guidelines for image in-
terpretation for CTC detection in non-metastatic breast
cancer. Continuous training, independent image review
and adherence to these consensus guidelines should be
considered in studies evaluating the clinical utility of
CTC-related biomarkers in non-metastatic breast cancer.Additional files
Additional file 1: Table S1. Agreement (%) between academic readers
and Veridex consensus (VC) according to dataset and disease stage.
Description of data: we observed significantly lower agreement between
academic readers and VC for CellSearch® images from patients of the
Institut Jules Bordet (IJB) dataset compared to the other datasets and
from patients with non-metastatic (M0) compared to metastatic (M1)
disease.
Additional file 2: Table S2. Agreement (%) between academic readers
and Veridex consensus (VC) according to circulating tumor cell (CTC)
count and administration of systemic therapy before blood sample
collection. Description of data: we observed significantly lower
agreement between academic readers and VC for CellSearch® images
from patients with <5 CTCs compared to ≥5 CTCs and blood samples
drawn after the administration of systemic treatment as compared to
samples drawn before systemic treatment.Abbreviations
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